aspirawh.com Open in urlscan Pro
2606:4700:20::681a:f04  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Products
   * * 
     * Find Out More
   * * Products
     * OvaSuite
       * OvaSuite
       * OvaSuite
       * OvaWatch
       * Ova1Plus
   * * Contact Us
     * Order a Kit
 * Providers
   * * 
     * Find Out More
   * * Providers
     * For Providers
       * For Providers
       * Research and Professional Guidelines
       * Clinical Studies
       * Events
       * Contact Aspira
   * * Contact Us
     * Order a Kit
 * Patients
   * * 
     * Find Out More
   * * Patients
     * For Patients
       * For Patients
       * Learn More About Adnexal Masses
       * Contact Aspira
   * * Contact Us
     * Pay My Bill
 * Investors
   * * * 
     * * Check out our
         Press Releases
       * Explore
   * * Investors
     * For Investors
       * For Investors
       * Investor Overview
       * News
       * Events & Presentations
     * Resources
       * Resources
       * SEC Filings
       * Stock Information
       * Corporate Governance
   * * Contact Us
     * News Alerts
 * About Us
   * * 
     * Find Out More
   * * About Us
     * About Aspira
       * About Aspira
       * About Aspira Women’s Health
       * Our History
       * Leadership
       * Clinical Advisory Board
       * News
       * Contact Us
       * Careers
       * Licensure & Legal – Aspira Labs
       * Code of Conduct
   * * Contact Us
     * Latest News

 * Follow Us:
 * News
 * Events
 * Contact Us


TRANSFORMING WOMEN’S GYNECOLOGIC HEALTH, STARTING WITH OVARIAN CANCER.

We believe that early detection of ovarian cancer risk is the first step to
drive better outcomes for the close to 20,000 cases of ovarian cancer diagnosed
each year1. We are working to transform women’s gynecological health with the
discovery, development, and commercialization of innovative testing options for
women of all races and ethnicities, regardless of menopausal status. Our
data-driven approach delivers solutions that help women take control of their
gynecologic health and empower providers to deliver optimal care.



Learn About Our Research


HEALTHCARE PROVIDERS HAVE ORDERED MORE THAN 200,000 OVASUITESM TESTS

--------------------------------------------------------------------------------

On September 20, 2023, Aspira Women’s Health hosted a Key Opinion Leader Webinar
on Assessing Ovarian Cancer Risk with OvaWatch℠. If you missed our live
discussion, you don’t have to miss out! Watch now to learn how OvaSuite℠ can
help give you confidence in making the right treatment decision for any patient
with an adnexal mass, regardless of age or menopausal status.


OUR PRODUCTS

--------------------------------------------------------------------------------

 * OvaWatch℠ is a non-invasive, blood-based test intended for use in the initial
   clinical assessment of ovarian cancer risk in women with benign or
   indeterminate adnexal masses for which surgical intervention may be either
   premature or unnecessary. With a negative predictive value (NPV) of over
   99%2, OvaWatch allows physicians to confidently rule out ovarian malignancy
   and choose the appropriate clinical management for the right patient at the
   right time.
   
   Learn More

 * Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk
   of ovarian malignancy in women with adnexal masses planned for surgery.
   
   Learn More


COMING SOON

--------------------------------------------------------------------------------

 * EndoCheck℠ is a first-of-its kind, non-invasive test intended to aid in the
   identification of endometriosis.

--------------------------------------------------------------------------------

Watch Aspira’s CEO, Nicole Sandford, and Clinical Advisory Board member, Dr.
Tamika Sea MD, FACOG, discuss the establishment of Aspira’s Clinical Advisory
Board, an element of its overall mission to develop and distribute high-impact
diagnostic tools for gynecologic disease with Jane King on New to The Street.

--------------------------------------------------------------------------------

On December 11, 2023, Aspira’s CEO, Nicole Sandford, SVP, Michelle Snider, and
Sales Rep. & Patient, Lottie Wilder, were interviewed by Jane King on New to The
Street to discuss Aspira’s commercial refresh, what’s ahead for the company, and
Lottie's personal health journey.


ASPIRA WOMEN’S HEALTH ANNOUNCES PUBLICATION OF REAL-WORLD DATA VALIDATING USE OF
OVAWATCH FOR THE MANAGEMENT OF ADNEXAL MASSES

--------------------------------------------------------------------------------

Read our new multi-site clinical study describing real-world evidence supporting
the use of OvaWatch for the clinical management of adnexal masses in Frontiers
in Medicine.


HEAR FROM THE EXPERTS

--------------------------------------------------------------------------------

 * > The diagnostic tools for ovarian cancer have not changed throughout my
   > entire career, but now with OvaWatch, we can assess the malignant potential
   > of a mass.
   > 
   > - Gerard Reilly, MD, FACOG

 * > This is definitely a clinical tool you want to have access to in your
   > office
   > 
   > - Tamika L. Sea, MD, FACOG

 * > Ova1® is great in that it can help to avoid second procedures on patients
   > and second operations which can be associated with higher morbidity.
   > 
   > - Jonathan Black MD, MPH

 * > Ova1Plus® has added to our armamentarium as physicians by decreasing the
   > false positive rate up to 50%
   > 
   > - Howard C. Mandel MD, FACOG

PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF
OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL
ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING
(ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT
PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH
ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE
DIAGNOSTIC ASSAY.

OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING
EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A
PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY
TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.


 1. https://seer.cancer.gov/statfacts/html/ovary.html
 2. Reilly G, Bullock RG, Greenwood J, Ure DR, Stewart E, Davidoff P, DeGrazia
    J, Fritsche H, Dunton CJ, Bhardwaj N, & Northrop LE. (2022). Analytical
    Validation of a Deep Neural Network Algorithm for the Detection of Ovarian
    Cancer. JCO Clin Cancer Inform 6:e2100192


CONTACT US

 * Tel: 844-ASPIRA1 (844-277-4721)
 * Fax: 866-283-3634

 * 12117 Bee Caves Road
   
   Building III, Suite 100
   
   Austin, TX 78738


 * INVESTORS
   
   * Investor Overview
   * Events & Presentations
   * SEC Filings
   * Corporate Governance
   * Stock Information


 * ABOUT US
   
   * About Aspira
   * Leadership
   * Licensure & Legal


 * NEWS
   
   * News
   * Educational Events


 * FOLLOW US
   
   * 
   * 
   * 
   * 
   * 

Copyright © 2024 Aspira Women's Health. All Rights Reserved. | Privacy Policy |
Website Design by Wyndetryst

Please note that we use cookies necessary for the functioning of our website,
and to optimize the performance. To learn more about our cookies, how we use
them and their benefits, please read our Cookie Policy.

I Understand